Abbvie Inc.

Abbvie Deutschland Gmbh and Co Kg

Lorenzo Benatuil

Chung-Ming Hsieh

Jennifer Maria Perez

Yuliya Kutskova

Jijie Gu

Andrew C Phillips

John Memmott

Edward B Reilly

Erwin R Boghaert

Susan Elizabeth Morgan-Lappe

Yingchun Li

Feng Dong

Jonathan A Hickson

Anca Clabbers

Maria Harris

Jacqueline G Bixby

Tariq Ghayur

Heinz Hillen

Ulrich Ebert

Andrew J Souers

Milan Bruncko

Ravi Chari

Andreas R Striebinger

Stefan Barghorn

Emma Fung

Suju Zhong

Jochen G Salfeld

Andrew S Judd

Maria A Argiriadi

Gillian A Kingsbury

Zhihong Liu

Carrie Goodreau

Simone Giaisi

Renee Miller

Lucia Eaton

Alyssa Brito

Jonathan P Belk

Margaret Hugunin

Liangjun Lu

Bradford L McRae

Susan E Lacy

Peter C Isakson

Preethi Krishnan

Meha Chhaya

Tatyana Dekhtyar

John E Harlan

Debra Chao

Axel Hernandez, Jr

Archana Thakur

Wendy Waegell

Kamel Izeradjene

Rui Wang

Sahana Bose

Diana Bowley

Russell A Judge

Matthew Rieser

David A Egan

Sarah J Heighton

Alexander Ivanov

Kangwen Deng

Gautam Sahu

Denise Karaoglu Hanzatian

Federico Mensa

Teresa (Iok-Chan) Ng

Jing Min

The present disclosure provides anti-&#x3b1;4&#x3b2;7 antibodies that bind human &#x3b1;4&#x3b2;7, their methods of making, and their uses to treat patients with HIV infection.

Anti-alpha-4-beta-7 antibodies

The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

Anti-B7-H3 antibodies and antibody drug conjugates

The present invention encompasses antagonist anti-CD40 antibodies and antigen-binding portions thereof. Specifically, the invention relates to humanized anti-CD40 antibodies. In certain embodiments, antibodies of the invention neutralize human CD40 (hCD40) activity. Antibodies, or antibody portions, of the invention are useful for detecting CD40 and for inhibiting CD40 activity, e.g., in a human subject suffering from a disorder in which CD40 activity is detrimental.

Anti-CD40 antibodies

The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

Anti-EGFR antibodies and antibody drug conjugates

The disclosure provides binding proteins that specifically bind to LRP-8 and optionally cross the blood brain barrier (BBB), localize to the brain and/or localize to the spinal cord.

LRP-8 binding dual variable domain immunoglobulin proteins

System and methods are disclosed for identifying and isolating antibodies with specific affinity with an antigen of interest. Multiple DNA libraries encoding antibodies or their fragments are designed such that the encoded antibodies from different libraries are tagged differently. These libraries may be transformed into yeast cells. The variants of the antibodies are displayed on the surface of the yeast cells and flow cytometry may be used to sort the cells based on antigen affinity and the different tags on the antibodies. By allowing multiple libraries to be screened simultaneously, the disclosed methods help improve the efficiency of affinity.

High-throughput system and method for identifying antibodies having specific antigen binding activities

Binding proteins that bind one or more of VEGF, PDGF and/or their receptors, including antibodies, CDR-grafted antibodies, humanized antibodies, binding fragments, fusion proteins, and bispecific or multispecific proteins thereof are disclosed. Also disclosed are methods of making and using the binding proteins.

Antibodies against platelet-derived growth factor (PDGF)

The present invention relates to amyloid-beta (A&#x3b2;) binding proteins. Antibodies of the invention have high affinity to A&#x3b2;(20-42) globulomer or any A&#x3b2; form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided.

Amyloid-beta binding proteins

Isolated binding proteins, e.g., antibodies or antigen binding portions thereof, which bind to tumor necrosis factor-alpha (TNF-&#x3b1;), e.g., human TNF-&#x3b1;, and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies.

Immunobinders directed against TNF

The disclosure provides binding proteins that specifically bind to IL-1&#x3b1; and IL-1&#x3b2;. These binding proteins can be organized into DVD-Igs. These proteins can be used to modulate the activity of IL-1&#x3b1; and/or IL-1&#x3b2; and can be used for the treatment immunological diseases such as rheumatoid arthritis, osteoarthritis, psoriasis, multiple sclerosis, and other autoimmune diseases. In addition, their uses in the amelioration and/or treatment of pain in an individual suffering from a disease or disorder associated with IL-1 accumulation.

IL-1 binding proteins

Engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease are provided.

Bispecific antibodies directed against TNF-&#x3b1; and IL-17

The present invention relates to improved methods for antibody engineering, e.g., humanization. In particular, the disclosure provides a high-throughput antibody humanization process that can be automated by computer-implementation.

High-throughput antibody humanization

Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.

Therapeutic DLL4 binding proteins

Growing community of inventors

Northborough, MA, United States of America

Lorenzo Benatuil